Expertise in Health Economic Modelling
Experienced Health Economist offering consulting services to assist on a range of HEOR related projects including budget impact and cost-effectiveness modelling to support HTA submissions across Europe and the US.
About me
Passionate Health Economist holding an MSc in Health Economics from The University of Manchester with several years of experience in the pharmaceutical consulting and public health industry undertaking decision-analytic modelling for cost-effectiveness, cost-utility, early threshold pricing, and budget impact analyses to support HTA submissions across Europe and the US for multinational pharmaceutical companies.
Expertise in developing models using R and Excel VBA, incorporating a range of biostatistical and econometric methods to inform healthcare policy for agencies such as the World Health Organisation.
Conducted economic evaluations across a broad range of disease areas including oncology, rare disease and genomics utilising clinical trial evidence. Work cross-functionally to manage economic models and evidence synthesis tasks to defined and strict timelines whilst liaising with clients to ensure high quality deliverables.
Synthesised technical reports, slide decks and manuscripts for publications across a range of healthcare topics.
For more information on the range of projects I have been involved with, please see below.
Project Portfolio
See below for the range of projects I have been involved with and details of the project.
-
Created a cost-consequence model to assess a wide range of costs and consequences of different interventions including the JADA® System, Bakri Balloon, Laparotomy and Uterotonics.
Results were reported separately without aggregating into a single measure or financial terms to see the effects on an isolated basis.
Created a deterministic sensitivity analysis macro which varied all model inputs by ±10% to see the magnitude of effect on the budget impact.
-
Created an OLS regression model utilising WHO vaccination coverage rates (VCR) across 21 European countries to estimate whether certain countries were on track to achieve the WHO recommended 90% vaccination coverage rate in HPV for 15 year olds by 2030.
The model would utilise statistical methods to analyse whether trends were following linear, exponential, logarithmic, power or 2nd order regressions and would then estimate the VCR in 2030 based on the current trend.
Created custom macros which would show the increase in VCR per year required to achieve a VCR by a specific year.
Second author in published manuscript: https://www.tandfonline.com/doi/full/10.1080/14760584.2024.2402535#abstract
-
Developed a US and UK focused cost-effectiveness model focused on redasemtide for the treatment of acute ischemic stroke.
Model outcomes included incremental cost effectiveness ratios, economically justifiable price and cost-effectiveness acceptability curves.
For the UK focus, model followed the National Institute for Clinical Excellence (NICE) health technology assessment (HTA) reference case requirements.
Created macros for deterministic sensitivity analysis and also scenario analysis for patients who had not received lytic or thrombectomy within 48 hours.
-
Created a US market focused budget impact model over a 5-year time horizon to compare pembrolizumab with chemoradiotherapy against standard of care.
Model could be viewed from both a payer and hospital perspective.
Worked closely with the client to develop the patient flow and epidemiology components of the model.
Created a deterministic sensitivity analysis macro which varied all model inputs by ±10% to see the magnitude of effect on the budget impact.
Model was also adapted for the Italy market (AIFA).
-
Created R Studio code which compared two mapping crosswalks (EuroQoL and DSU) to see which had greater predictive accuracy.
Analsyis was run on two datasets where patients filled out EQ-5D-5L and 3L forms which was then compared to the results produced by the crosswalks in order to determine their predicitive accuracy.
-
Created a US market focused budget impact model over a 5-year time horizon to compare pembrolizumab against standard of care.
Model could be viewed from both a payer and hospital perspective.
Created a deterministic sensitivity analysis macro which varied all model inputs by ±10% to see the magnitude of effect on the budget impact.
-
Created a US market focused budget impact model over a 5-year time horizon to compare pembrolizumab against standard of care.
Model could be viewed from both a payer and hospital perspective.
Created a deterministic sensitivity analysis macro which varied all model inputs by ±10% to see the magnitude of effect on the budget impact.
-
Created a US market focused budget impact model over a 5-year time horizon to compare pembrolizumab plus adjuvant chemotherapy against standard of care.
Model could be viewed from both a payer and hospital perspective.
Created a sensitivity macro which varied all model inputs by ±10% to see the magnitude of effect on the budget impact.
-
A human capital approach was used to estimate productivity losses due to premature death from several cancer indications across Asia-Pacific countries.
The model had three outcomes of interest: years of life lost, years of productive life lost and present value of future lost productivity.
Created a deterministic sensitivity analysis analysis macro which varied inputs by ± 10% to gauge their impact on the outcomes.
-
Built a combined cost-effectiveness and budget impact model comparing the use of anti-PD-(L1) inhibitors versus currrent standard of care in different cancer indications such as cervical and metastatic triple negative breast cancer.
Model outputs included the increase in QALYs, life years gained and budget impact for a population.
Results were presented to policymakers by myself in a slide deck format alongside an accompanying report.
Contact
Interested in working together? Fill out some details regarding the nature of your projects and assistance required and I will be in touch shortly.
